![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CARDIOVASCULAR
Clinical and Experimental Therapeutics Program, University of Georgia College of Pharmacy (A.E., A.K.H., J.H.), Vascular Biology Center (A.E., A.T., M.P.A.), Departments of Surgery (A.R., E.R., B.W., M.P.A.) and Pharmacology and Toxicology (R.W.C.), Medical College of Georgia, Augusta, Georgia; and University of Tromsø Institute of Pharmacy, Tromsø, Norway (J.S.J., C.S.)
Received September 17, 2004; accepted December 6, 2004.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
production plays an important role in diabetic complications by causing vascular dysfunction. The potent vasoconstrictor endothelin-1 (ET-1) is also elevated in diabetes and following CABG; however, the effect of ET-1 on 
generation and/or vascular dysfunction in bypass conduits remain unknown. Accordingly, this study investigated basal and ET-1-stimulated production in bypass conduits and determined the effect of on conduit reactivity. Saphenous vein specimens were obtained from nondiabetic (n = 24) and diabetic (n = 24) patients undergoing CABG. Dihydroethidium staining and NAD(P)H oxidase activity assays (5380 ± 940 versus 16,362 ± 2550 relative light units/µg) demonstrated increased basal levels in the diabetes group (p < 0.05). Plasma ET-1 levels were associated with elevated basal levels, and treatment of conduits with exogenous ET-1 further increased production and augmented vasoconstriction. Furthermore, vascular relaxation was impaired in the diabetic group (75 versus 40%), which was restored by scavenger superoxide dismutase. These findings suggest that ET-1 causes bypass conduits dysfunction via stimulation of production in diabetes. Novel therapies that attenuate generation in bypass conduits may improve acute and late outcome of CABG in diabetic patients.
). This, in part, explains why diabetic patients suffer a high incidence of unfavorable cardiac events in the postoperative period (Cohen et al., 1998). Adverse CABG outcomes in diabetic patients are most likely to be multifactorial, but properties of bypass conduits may directly contribute to vascular dysfunction both in the acute and late phase. Excess generation of reactive oxygen species (ROS), especially , can alter vascular function not only by reducing nitric oxide (NO) bioavailability and thereby impairing the vasorelaxation response acutely, but also generating hydrogen peroxide (H2O2) and cytotoxic peroxynitrite (ONOO–). These molecules can directly stimulate growth of vascular smooth muscle cells, which may contribute to graft stenosis (Griendling and FitzGerald, 2003a,b). ONOO– can alter function of biomolecules by protein nitration and lipid peroxidation (Turko et al., 2001) as well as causing single-strand DNA breakage and endothelial cell apoptosis (Soriano et al., 2001), all of which might contribute to graft stenosis in the late phase. Guzik et al. (2000, 2002) demonstrated that enhanced generation in bypass conduits of diabetic patients is mediated by NAD(P)H oxidase and uncoupled nitric-oxide synthase (eNOS). However, the effect of increased generation in diabetes on contractile properties of bypass conduits is not clear.
ET-1 is a potent vasoactive peptide with mitogenic properties. Elevated plasma levels of ET-1 have been reported in atherosclerosis and diabetes as well as during and following CABG surgery (Lerman et al., 1991). CABG results in a biphasic increase in circulating ET-1 levels, which is associated with a complex recovery in the immediate postoperative period. Higher plasma ET-1 levels are associated with longer intensive care unit stay (Dorman et al., 2000). Furthermore, there is a positive correlation between conduit sensitivity to ET-1 and a prolonged need for vasodilator support with nitroglycerin (Bond et al., 2001). These observations provide evidence that increased ET-1 levels may negatively impact outcome in CABG patients. Yet, the mechanism by which ET-1 alters bypass conduit function in diabetes remains to be determined.
Li et al. (2003) found that ET-1 stimulates production via activation of NAD(P)H oxidase in an experimental model of hypertension. In contrast, ET-1-mediated excess generation of in human smooth muscle cells is primarily of mitochondrial origin (Touyz et al., 2004). Therefore, mechanisms of ET-1-mediated production may be different in experimental models versus humans and further varies in disease states. To better understand the vasoactive processes that might influence function of CABG conduits, this study aimed to 1) determine whether and to what extent affects reactivity of bypass conduits, and 2) determine the effect of ET-1 on production in CABG conduits in diabetes and identify the mechanisms involved.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Vascular Reactivity. After the fat tissue was carefully removed, SV was cut into 2- to 3-mm rings, and the rings were mounted at the optimal diastolic tension (2 g) in 5-ml tissue baths containing oxygenated Krebs buffer maintained at pH 7.4 and 37°C. Isometric contractions were recorded with digital force transducers that are integrated with a myograph data acquisition system (Danish Technologies, Copenhagen, Denmark). After the rings were equilibrated for 1 h, rings were challenged with 70 mM KCl to assess the viability. At plateau, the integrity of endothelium was tested by 100 nM acetylcholine (ACh). In endothelium-intact vessels, the dose-response curves were generated using progressive concentrations of ET-1 (1–200 nM), and the contractile response obtained with each concentration of ET-1 were expressed as percentage of tension generated by 70 mM KCl per gram of tissue. To determine the role of in modulating the contractile response, additional rings were incubated with 150 U/ml polyethylene glycol-conjugated superoxide dismutase (PEG-SOD) for 30 min after the equilibration step, and the dose-response curve to ET-1 was generated in the presence of PEG-SOD. To determine whether the augmented contractility is specific for ET-1 in a subset of patients (n = 6), contractile response to 1 µM phenylephrine (PE) was assessed. For vascular relaxation studies, after washing and equilibration for at least 30 min, rings were precontracted with 10 nM ET-1 for 30 min followed by a dose-response curve for ACh (1 nM–10 µM). The vasodilatation induced was expressed as percentage of relaxation of ET-1-generated contractile response. Similar to ET-1 dose-response curve experiments, vasorelaxation experiments were performed in the presence of PEG-SOD as described above.
Dihydroethidium (DHE) Fluorescence. In situ superoxide generation was evaluated in vascular cryosections with the oxidative fluorescent dye DHE. Cryosections (16 µm) were incubated with DHE (2 µM) in phosphate-buffered saline with or without PEG-SOD (150 U/ml), which was added 30 min prior to staining. Fluorescence images were obtained with a BioRad MRC 1024 scanning confocal microscope. For each slide, at least five images from different sections of the slide were captured, and average staining intensity with Metamorph Software was calculated.
NADPH Oxidase Activity. The tissue was stored at –80°C until it was pulverized using liquid nitrogen and further homogenized in Tris-HCl buffer (50 mM Tris-HCl, 1 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, and 1 µg/ml pepstatin). The homogenate was centrifuged for 20 min at 4000 rpm at 4°C. The supernatant was further centrifuged in an ultracentrifuge for 45 min at 60,000 rpm at 4°C. The supernatant was saved as the cytosolic fraction and the pellet was resuspended in 100 µl of buffer as the particulate membrane fraction. Superoxide was measured using the luminol derivative L-012, which has been recently shown to be more sensitive than lucigenin and not to undergo redox recycling (Daiber et al., 2004). Briefly, 10 µg of total protein (cytosolic or membrane fraction) was added to a total volume of 300 µl of Krebs-Hepes buffer supplemented with 10 µM NADH, 200 µM L-012, and 100 µM sodium orthovanadate in a 96-well microplate luminometer. Background was read for 5 min before adding the protein. The luminometer was programmed to read each well for 5 to 10 s/min in 15 min. Counts normalized with background subtraction were expressed as relative light units per minute per micrograms of protein (RLU/min · µg). Because L-012 is light sensitive all work with L-012 was done in the dark. The specificity of L-012 for was confirmed by addition of SOD (150 U/ml), which decreased the luminescence to background levels in cell-free experiments as well as in measurements with tissue homogenates.
Measurement of ET-1. The amount of ET-1 in the plasma was determined using an enzyme-linked immunoassay kit specifically designed for direct measurement of plasma ET-1 (American Research Products, Belmont, MA) as we previously described (Ergul et al., 1996).
Western Analysis. Protein levels and membrane translocation of cytoplasmic NAD(P)H oxidase subunits p47phox and p67phox (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were determined by immunoblotting using specific antibodies. Vascular extracts (20 µg) were diluted to the appropriate loading concentration in sample buffer containing 0.1 M Tris-HCl, 4% SDS, and 0.01% bromophenol blue and loaded onto a 10% SDS-polyacrylamide gel. Samples were then separated at 40 mA using a Tris-glycine running buffer (0.2 M Tris-base, 0.2 M glycine, pH 6.8, and 0.1% SDS). The separated samples were transferred to a nitrocellulose membrane in Trisglycine transfer buffer supplemented with 20% methanol. The immunoblots were blocked for 1 h in blocking grade powdered goat milk (5%) diluted in 0.2 M Tris-base, 1.4 M NaCl, 0.1% Tween 20, and 0.02% NaN3, followed by incubation with the primary antibodies for 24 h for p47phox and 48 h for p67phox. After incubation with the secondary antibody (goat anti-rabbit IgG from Santa Cruz Biotechnology Inc.), the bands corresponding to p47phox or p67phox were visualized using the Supersignal West Pico chemiluminescent substrate development kit. Equal protein loading in each gel was verified by immunoblotting for 
-actin.
Data Analysis. The immunoblots were analyzed by densitometric scanning. The data were compared with multiple analysis of variance or by Student's t test where appropriate. Results are given as mean ± S.E.M. An 
level of p < 0.05 was considered to be statistically significant.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
|
Impaired vascular relaxation is a well described phenomenon of endothelial dysfunction in diabetes. To determine whether and to what extent the dilatory response of SV conduits is blunted in diabetes, endothelium-dependent vasorelaxation was assessed using ACh. Maximum relaxation was significantly lower in the SV specimens obtained from diabetic patients (46 versus 70% in nondiabetic patients). The presence of PEG-SOD significantly improved the vasorelaxation response in diabetics (Fig. 2).
|
Increased Basal and ET-1-Mediated Vascular Production in Diabetes. Since the vascular reactivity experiments provided evidence for involvement of in vascular dysfunction in diabetes, production was determined using DHE fluorescence. The basal levels were significantly higher in the diabetic group as evidenced by increased DHE fluorescence (Fig. 3), which was inhibited by the application of PEG-SOD providing evidence that DHE staining is due to . In light of the results of the vascular reactivity experiments showing that augments ET-1-mediated vasoconstriction, the effect of ET-1 on production was also investigated. Vascular rings were stimulated with 100 nM ET-1 for 30 min, which caused a significant increase in formation in both groups (Fig. 3B). Lower concentrations of ET-1 (10 nM) also increased DHE fluorescence by 27% in the diabetic group (data not shown).
|
To further investigate sources of generation in bypass conduits, NAD(P)H oxidase activity in the cytosolic and membrane fractions of vascular homogenates was examined using chemiluminescent dye L-012. Basal superoxide production in the membrane fractions in nondiabetic and diabetic groups was 5380 ± 940 and 16,362 ± 4551 RLU/min · µg, respectively (Fig. 4A). The presence of nonspecific [100 µM diphenyleneiodonium (DPI)] and relatively specific (30 µM apocynin) inhibitors of NAD(P)H attenuated generation by approximately 50%. Interestingly, N
-nitro-L-arginine inhibited 
by 33% in diabetic but not in nondiabetic samples suggesting that NOS, which may be uncoupled in the diabetic specimens, contributes to generation. The scavenger tiron (10 mM) reduced the NAD(P)H oxidase-mediated increase in levels in the diabetic group to comparable levels in the nondiabetic group. As expected, NAD(P)H oxidase activity in the cytosolic fractions was only slightly higher than background levels (
150–200 RLU/min · µg) in both diabetic or nondiabetic groups.
|
To determine the effect of ET-1 on NAD(P)H oxidase activity, SV samples (n = 5/group) were incubated with 100 nM ET-1 for 30 min, and oxidase activity was then measured. As shown in Fig. 4B, ET-1 had no effect on membrane NAD(P)H oxidase activity in either group. ET-1 stimulation did not alter the low cytosolic oxidase activity in either group.
Plasma ET-1 Levels. Systemic ET-1 levels in the preoperative period were significantly higher in the diabetic group (Fig. 5). To examine the relationship between ET-1 levels and basal superoxide production, linear regression analysis was performed. A positive linear relationship was observed between plasma ET-1 and NAD(P)H activity with r = 0.72 and p < 0.001. However, incubation of specimens with a combination of ETA (BQ-123) and ETB (BQ-788) antagonists did not have an effect on basal NAD(P)H activity in either group (data not shown).
|
Tissue Levels and Translocation of NAD(P)H Oxidase Subunits in Diabetes. NAD(P)H oxidase consists of two membrane, p22phox and p91phox (nox-1 or nox-4 homologs in vascular smooth muscle cells), and 3 cytosolic subunits, p40phox, p47phox, and p67phox, which are translocated to the membrane upon activation. Therefore, tissue levels of p47phox and p67phox subunits were assayed in the cytosolic and pellet (membrane) fractions to determine whether ET-1 promotes translocation of these subunits and thereby activation of NAD(P)H oxidase (Fig. 6). The p47phox subunit was detected primarily in the cytosolic fraction, and protein levels were slightly higher in the diabetic group. ET-1 stimulation increased protein levels in the cytosolic fraction but did not promote the translocation of this subunit to the membrane. Bands corresponding to p67phox subunit were detected in the cytosolic fractions but higher molecular weight bands around 90 kDa (possibly p22phox and p67phox complex) were also found in the membrane fractions. There was no difference in the protein expression level of this subunit between the study groups. Furthermore, ET-1 stimulation (100 nM for 30 min) did not affect the protein expression or the translocation to the membrane.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
production in bypass conduits, which is associated with increased plasma ET-1 levels. Although NAD(P)H oxidase plays an integral role in production under basal conditions, ET-1-stimulated generation in vitro does not appear to involve activation of NAD(P)H oxidase. These results suggest that ET-1 mediates vascular dysfunction of saphenous vein conduits and provide important evidence suggesting that redox-sensitive mechanisms may contribute to increased complication rates observed in diabetic CABG patients.
ET-1, a potent vasoactive peptide, has been shown to mediate vasoconstriction of the pulmonary and systemic circulation and influence myocardial contractility (Wenzel et al., 1998; Fleisch et al., 2000). All these effects are relevant to patients undergoing CABG. Bond and colleagues (2001) reported that circulating ET-1 levels increase during CABG surgery in a biphasic manner. Furthermore, prolonged pharmacologic management and lengthened intensive care unit stay are associated with elevated plasma ET-1 and increased bypass conduit sensitivity to ET-1 (Dorman et al., 2000). However, whether and to what extent ET-1 contributes to vascular dysfunction in high-risk patients remained unknown. In light of the observations that increased ET-1 levels are associated with diabetic complications (Hattori et al., 1991) and that diabetic patients are more prone to postoperative complications (Herlitz et al., 2000), we specifically investigated plasma ET-1 levels and ET-1-mediated graft reactivity in diabetic patients. Results of this study demonstrate that vasoconstrictor response to ET-1, not to PE, is heightened in the saphenous vein specimens from diabetic patients. Incubation of vessels with scavenger PEG-SOD improved contractile response providing evidence that augments ET-1-mediated vasoconstriction. Vasorelaxation capacity of graft conduits is equally important since many CABG patients require vasodilator treatment. In the current study, we demonstrate that endothelium-dependent vasorelaxation of bypass conduits preconstricted with ET-1 is impaired in diabetic patients via excess generation of . Although the impact of altered conduit reactivity on postoperative outcome measures was not studied, increased ROS may influence vascular function by several pathways. First, immediately reacts with NO generating ONOO– and reducing NO bioavailability. Since NO is one of the major pathways involved in vasorelaxation, this may directly impair the dilator response in patients with diabetes. Second, ONOO– can oxidize tetrahydrobiopterin, an important cofactor for eNOS, and this will lead to decreased NO and increased superoxide formation by eNOS. Third, ONOO– may cause nitration of downstream proteins involved in vasorelaxation such as large conductance Ca2+-activated (BKCa) and ATP-dependent (KATP) potassium channels. Liu and Gutterman (2002) showed that ONOO– inhibits BKCa channels resulting in reduced vasorelaxation of coronary arterioles, and this reduced activity is associated with strong staining for nitrotyrosine in this vascular bed. Another group recently reported that vasodilator responses to K+ channel openers are reduced in two experimental models of insulin resistance, and increased production is responsible for impaired relaxation (Erdos et al., 2004). Therefore future studies are needed to specifically investigate the regulation of K+ channels by ROS in human bypass graft conduits.
Vascular sources that augment reactive species generation include NAD(P)H oxidase, xanthine oxidase, NOS, lipooxygenases, and mitochondrial respiratory chain enzymes (Guzik et al., 2000, 2002; Brownlee, 2001; Aliciguzel et al., 2003). NAD(P)H oxidase, a membrane associated enzyme, is a major source of production in the vasculature (Guzik et al., 2000, 2002; Etoh et al., 2003; Kitada et al., 2003; Endemann and Schiffrin, 2004). Similar to neutrophil (phagocytic) oxidase, vascular enzyme is also composed of multiple subunits (Taniyama and Griendling, 2003). Cytoplasmic subunits (p40phox, p47phox, and p67phox) are translocated to the membrane where they associate with the membrane subunits p22phox and gp91phox (or homologs nox1 and nox4) to form the active enzyme. There is recent evidence that novel homologues of p47phox (p41nox or NOXO1) and p67phox (p51nox or NOXA1) can substitute for p47phox and p67 phox (Banfi et al., 2003; Takeya et al., 2003; Griendling, 2004). Guzik et al. (2000, 2002) demonstrated that there is enhanced production of NAD(P)H oxidase-mediated in the bypass conduits (both internal mammary artery and saphenous veins) obtained from patients with diabetes, and this is accompanied by increased expression of the subunit proteins. In contrast to our and Guzik's findings, Huraux and colleagues (1999) reported no differences in superoxide levels or vasorelaxation in internal mammary artery segments obtained from patients with identified cardiovascular risk factors, but they did not specifically investigate the effect of diabetes, which may explain the difference in their findings. Results of our current study confirm that NAD(P)H oxidase activity is significantly higher in bypass conduits obtained from diabetic patients. Apocynin inhibits generation by blocking the subunit association of NADPH oxidase, but if the subunit complex is already formed, it does not inhibit free radical formation. Since basal levels were measured without any stimulation, we suspect there is significant NADPH complex already formed and that is why apocynin and DPI failed to inhibit NAD(P)H oxidase activity completely. Consistent with increased basal activity, we detected complexes of cytoplasmic and membrane subunits in the membrane fractions of vascular homogenates. We also found that plasma ET-1 levels are significantly higher in the diabetic patients, and this is associated with enhanced superoxide production in diabetic patients. However, incubation of vessels with mixed ET receptor antagonists did not reduce the increased basal activity detected in the specimens obtained from diabetic patients. One possible explanation is that elevated ET-1 levels might have already stimulated downstream targets of ROS production in diabetes; thus, blockade of ET receptors in vitro does not have an effect on basal NAD(P)H oxidase activity.
Based on our results with modulation of ET-1-mediated vascular reactivity by and elevated plasma ET-1 levels in diabetic patients undergoing CABG, we asked whether ET-1 stimulates ROS generation in graft conduits and identify the mechanisms involved. DHE staining of SV specimens stimulated with ET-1 demonstrated increased production in both patient groups, which was more pronounced in the diabetic group. Li et al. (2003) demonstrated that ET-1 increases vascular generation via NAD(P)H oxidase. Based on the findings by Guzik (2000, 2002) and Li (2003), we hypothesized that ET-1 induces production by promoting the translocation of p47phox and p67phox cytoplasmic subunits of NAD(P)H oxidase to the membrane compartment and activating the oxidase as seen by angiotensin II (Ang II) stimulation (Touyz et al., 2002). To test this hypothesis, we measured oxidase activity in SV specimens stimulated with ET-1 as well as determining the protein levels of p47phox and p67phox in cytoplasmic and membrane fractions prepared from bypass conduits stimulated with ET-1. To our surprise, there was no change in NAD(P)H oxidase activity in ET-1-stimulated tissue in either the diabetic or nondiabetic group. ET-1 stimulation also failed to cause a shift of p47phox and p67phox from the cytoplasm to membrane. In light of the recent evidence that NOXO1 and NOXA1 can substitute for p47phox and p67phox, respectively, one possibility is that ET-1 may stimulate these novel homologues and not conventional cytoplasmic subunits of NAD(P)H oxidase. Due to lack of specific antibodies for these homologues, we could not investigate this possibility. A recent study by Touyz et al. (2004) reported that Ang II and ET-1 regulate mitogen-activated protein kinases through different redox-dependent pathways in human vascular smooth muscle cells. Although Ang II induces NAD(P)H oxidase-mediated ROS, ET-1 predominantly stimulates the generation of mitochondrial-derived superoxide suggesting that mechanisms of ET-1-mediated production might be different in human tissue and in disease states. These results provide support for our findings and warrant future studies focusing on the role of mitochondria in ET-1-mediated ROS generation.
Limitations of this study must be recognized. All patients had coronary artery disease. Although vascular tissue specimens used in this study were considered relatively healthy and utilized for bypass conduits, we cannot differentiate the impact of coronary artery disease on these ROS-generating systems in our study population. Second, we only evaluated saphenous vein conduits since the amount of internal mammary artery, another commonly used bypass conduit, is quite limited. Third, all the patients were receiving pharmacotherapy for comorbid conditions. Although medications, age, and comorbid conditions appear to be similar in both groups, in the diabetes group, there were more African American patients, and the number of subjects in each group is small for multivariate analyses. Complex drug interactions, ethnic differences, and effects of concurrent diseases on oxidative stress markers remain potential confounding factors. Nevertheless, the findings of this study demonstrate that ET-1 alters bypass conduit reactivity, in part, by stimulating excess formation of ROS in diabetes. This study also provides novel evidence that ET-1 induces via a non-NAD(P)H dependent mechanism in the venous grafts. Although acute modulation of the tone of bypass graft conduits by may be critical for the pharmacological management of postoperative vasospasm, long-term consequences may be increased proliferative response to vascular injury as shown in an experimental venous bypass grafts (West et al., 2001). Since the long-term results of CABG are limited by stenosis and subsequent occlusion of SV grafts, the most commonly utilized conduit for these operative procedures (Angelini and Newby, 1989; Cox et al., 1991; Bryan and Angelini, 1994; Davies and Hagen, 1995; Davies et al., 1998), ET receptor antagonism may offer a therapeutic benefit especially in high-risk diabetic patients.
|
Footnotes |
|---|
ABBREVIATIONS: CABG, coronary artery bypass grafting; ROS, reactive oxygen species; NO, nitric oxide; , superoxide; ONOO–, peroxynitrite; NOS, nitric-oxide synthase; eNOS, endothelial NOS; ET-1, endothelin-1; SV, saphenous vein; ACh, acetylcholine; PEG-SOD, polyethylene glycol-conjugated superoxide dismutase; PE, phenylephrine; L-012, 8-amino-5-chloro-7-phenylpyrido[3,4-d]pyridazine-1,4-(2H,3H)dione; RLU/min · µg, relative light units per minute per micrograms of protein; DHE, dihydroethidium; DPI, diphenyleneiodonium; BQ-123, cyclo(L-Leu-D-Trp-D-Asp-L-Pro-D-Val); BQ-788, N-[(cis-2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-L-leucyl-1-(methoxycarbonyl)-D-tryptophyl-D-norleucine; Ang II, angiotensin II.
Address correspondence to: Dr. Adviye Ergul, Medical College of Georgia, Clinical Pharmacy CJ-1020, 1120 15th Street, Augusta, GA 30912. E-mail: aergul{at}mail.mcg.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Aliciguzel Y, Ozen I, Aslan M, and Karayalcin U (2003) Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 142: 172–177.[CrossRef][Medline]
Angelini GD and Newby AC (1989) The future of saphenous vein as a coronary artery bypass conduit. Eur Heart J 10: 273–280.
Banfi B, Clark RA, Steger K, and Krause KH (2003) Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 278: 3510–3513.
Bond BR, Dorman BH, Clair MJ, Walker CA, Pinosky ML, Reeves ST, Walton S, Kratz JM, Zellner JL, Crumbley AJ 3rd, et al. (2001) Endothelin-1 during and after cardiopulmonary bypass: association to graft sensitivity and postoperative recovery. J Thorac Cardiovasc Surg 122: 358–364.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature (Lond) 414: 813–820.[CrossRef][Medline]
Bryan AJ and Angelini GD (1994) The biology of saphenous vein graft occlusion: etiology and strategies for prevention. Curr Opin Cardiol 9: 641–649.[Medline]
Cohen Y, Raz I, Merin G, and Mozes B (1998) Comparison of factors associated with 30-day mortality after coronary artery bypass grafting in patients with versus without diabetes mellitus. Israeli Coronary Artery Bypass (ISCAB) Study Consortium. Am J Cardiol 81: 7–11.[CrossRef][Medline]
Cox JL, Chiasson DA, and Gotlieb AI (1991) Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 34: 45–68.[CrossRef][Medline]
Daiber A, August M, Baldus S, Wendt M, Oelze M, Sydow K, Kleschyov AL, and Munzel T (2004) Measurement of NAD(P)H oxidase-derived superoxide with the luminol analogue L-012. Free Radic Biol Med 36: 101–111.[CrossRef][Medline]
Davies MG and Hagen PO (1995) Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 9: 7–18.[CrossRef][Medline]
Davies MG, Huynh TT, Fulton GJ, Lefkowitz RJ, Svendsen E, Hagen PO, and Koch WJ (1998) G protein signaling and vein graft intimal hyperplasia: reduction of intimal hyperplasia in vein grafts by a Gbetagamma inhibitor suggests a major role of G protein signaling in lesion development. Arterioscler Thromb Vasc Biol 18: 1275–1280.
Dorman BH, Bond BR, Clair MJ, Walker CA, Pinosky ML, Reeves ST, Kratz JM, Zellner JL, Crumbley AJ 3rd, Multani MM, et al. (2000) Temporal synthesis and release of endothelin within the systemic and myocardial circulation during and after cardiopulmonary bypass: relation to postoperative recovery. J Cardiothorac Vasc Anesth 14: 540–545.[CrossRef][Medline]
Endemann DH and Schiffrin EL (2004) Nitric oxide, oxidative excess and vascular complications of diabetes mellitus. Curr Hypertens Rep 6: 85–89.[Medline]
Erdos B, Snipes JA, Miller AW, and Busija DW (2004) Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 53: 1352–1359.
Ergul S, Parish CD, Puett D, and Ergul A (1996) Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension 28: 652–655.
Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, and Nawata H (2003) Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46: 1428–1437.[CrossRef][Medline]
Fleisch M, Sutsch G, Yan XW, Wenzel RR, Binggeli C, Bianchetti MG, Meier B, Kiowski W, and Luscher TF (2000) Systemic, pulmonary and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular function. J Cardiovasc Pharmacol 36: 302–309.[CrossRef][Medline]
Griendling KK (2004) Novel NAD(P)H oxidases in the cardiovascular system. Heart 90: 491–493.
Griendling KK and FitzGerald GA (2003a) Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108: 1912–1916.
Griendling KK and FitzGerald GA (2003b) Oxidative stress and cardiovascular injury: part II: animal and human studies. Circulation 108: 2034–2040.
Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, and Channon KM (2002) Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656–1662.
Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, and Channon KM (2000) Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res 86: E85–E90.
Hattori Y, Kasai K, Nakamura T, Emodo T, and Shimoda S-I (1991) Effects of glucose and insulin on immunoreactive endothelin-1 release from cultured bovine endothelial cells. Metabolism 40: 165–169.[CrossRef][Medline]
Herlitz J, Caidahl K, Wiklund I, Sjoland H, Karlson BW, Karlsson T, Haglid M, and Hartford M (2000) Impact of a history of diabetes on the improvement of symptoms and quality of life during 5 years after coronary artery bypass grafting. J Diabetes Complic 14: 314–321.[CrossRef][Medline]
Huraux C, Makita T, Kurz S, Yamaguchi K, Szlam F, Tarpey MM, Wilcox JN, Harrison DG, and Levy JH (1999) Superoxide production, risk factors and endothelium-dependent relaxations in human internal mammary arteries. Circulation 99: 53–59.
Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A, and Haneda M (2003) Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 52: 2603–2614.
Lerman A, Edwards BS, Hallet JW, Heublein DM, Sandberg SM, and Burnett SMJ (1991) Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 325: 997–1001.[Abstract]
Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, and Chen AF (2003) Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 107: 1053–1058.
Liu Y and Gutterman DD (2002) The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vasc Pharmacol 38: 43–49.
Soriano FG, Virag L, and Szabo C (2001) Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation. J Mol Med 79: 437–448.[CrossRef][Medline]
Stewart RD, Campos CT, Jennings B, Lollis SS, Levitsky S, and Lahey SJ (2000) Predictors of 30-day hospital readmission after coronary artery bypass. Ann Thorac Surg 70: 169–174.
Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, and Sumimoto H (2003) Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem 278: 25234–25246.
Taniyama Y and Griendling KK (2003) Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42: 1075–1081.
Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, and Schiffrin EL (2002) Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 90: 1205–1213.
Touyz RM, Yao G, Viel E, Amiri F, and Schiffrin EL (2004) Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 22: 1141–1149.[CrossRef][Medline]
Turko IV, Marcondes S, and Murad F (2001) Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. Am J Physiol 281: H2289–H2294.
Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, Jones CR, Clozel M, Meier B, and Luscher TF (1998) Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 98: 2235–2240.
West NEJ, Guzik TJ, Black E, and Channon KM (2001) Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 21: 189–194.
This article has been cited by other articles:
|
|
 |
|
  K. G. Maier Nicotinamide Adenine Dinucleotide Phosphate Oxidase and Diabetes: Vascular Implications Vascular and Endovascular Surgery, August 1, 2008; 42(4): 305 - 313. [Abstract] [PDF]
|
|
|
|
 |
|
 F. Bohm and J. Pernow The importance of endothelin-1 for vascular dysfunction in cardiovascular disease Cardiovasc Res, October 1, 2007; 76(1): 8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sachidanandam, A. Harris, J. Hutchinson, and A. Ergul Microvascular versus macrovascular dysfunction in type 2 diabetes: differences in contractile responses to endothelin-1. Experimental Biology and Medicine, June 1, 2006; 231(6): 1016 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Obrosova, V. R. Drel, P. Pacher, O. Ilnytska, Z. Q. Wang, M. J. Stevens, and M. A. Yorek Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited Diabetes, December 1, 2005; 54(12): 3435 - 3441. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
